Article Text

other Versions

PDF
Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis
  1. Lars G Hemkens1,
  2. Hannah Ewald1,
  3. Viktoria L Gloy1,
  4. Armon Arpagaus1,
  5. Kelechi K Olu1,
  6. Mark Nidorf2,
  7. Dominik Glinz1,
  8. Alain J Nordmann1,
  9. Matthias Briel1,3,4
  1. 1Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland
  2. 2Heart Care Western Australia, Perth, Australia
  3. 3Department of Clinical Research, University of Basel, Basel, Switzerland
  4. 4Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada
  1. Correspondence to Dr Lars G Hemkens, Basel Institute for Clinical Epidemiology & Biostatistics, University Hospital Basel, CH-4031 Basel, Switzerland; lars.hemkens{at}usb.ch

Abstract

Colchicine is an old anti-inflammatory drug that has shown substantial cardiovascular benefits in recent trials. We systematically reviewed cardiovascular benefits and harms of colchicine in any population and specifically in patients with high cardiovascular risk. We evaluated randomised controlled trials comparing colchicine over at least 6 months versus any control in any adult population. Primary outcomes were all-cause mortality, myocardial infarction and adverse events. Cardiovascular mortality was a secondary outcome. We included 39 trials with 4992 patients. The quality of evidence for mortality outcomes and myocardial infarction was moderate but lower for adverse events. Colchicine had no effect on all-cause mortality (RR 0.94, 95% CI 0.82 to 1.09; I2=27%; 30 trials). Cardiovascular mortality was reduced in some but not all meta-analytical models (random-effects RR 0.34, 0.09 to 1.21, I2=9%; Peto's OR 0.24, 0.09 to 0.64, I2=15%; Mantel-Haenszel fixed-effect RR 0.20, 0.06 to 0.68, I2=0%; 7 trials). The risk for myocardial infarction was reduced (RR 0.20, 0.07 to 0.57; 2 trials). There was no effect on total adverse events (RR 1.52, 0.93 to 2.46, I2=45%; 11 trials) but gastrointestinal intolerance was increased (RR 1.83, 1.03 to 3.26, I2=74%; 11 trials). Reporting of serious adverse events was inconsistent; no event occurred over 824 patient-years (4 trials). Effects in high cardiovascular risk populations were similar (4 trials; 1230 patients). We found no evidence supporting colchicine doses above 1 mg/day. Colchicine may have substantial cardiovascular benefits; however, there is sufficient uncertainty about its benefit and harm to indicate the need for large-scale trials to further evaluate this inexpensive, promising treatment in cardiovascular disease.

View Full Text

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles